Fig. 2From: Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature reviewTimeline of treatment shows the administration of multiple therapeutic approachesBack to article page